Chronic administration of hydroxyurea (HU) benefits caucasian patients with sickle-beta thalassemia

8Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

Abstract

In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (<15 mg/kg/day) are beneficial. We reviewed the medical records of 140 patients from 2010 to 2014. The laboratory parameters and SCD complications were compared between the first and last visits based on HU use. Fifty patients (36%) never took HU or suspended HU (“no HU” group). Among patients taking <15 mg/kg/day HU on their first visit, half remained at the same dose, and the other half increased to ≥15 mg/kg/day. Among patients taking ≥15 mg/kg/day, 17% decreased to <15 mg/kg/day, and 83% stayed at ≥15 mg/kg/day. The “no HU” group had fewer episodes of VOC and ACS. Both HU treatment groups had a reduction in both complications (p < 0.0001). This improvement was observed in all SCD phenotypes. The white blood cell (WBC) counts were found to be lower, and HbF increased in both HU groups (p = 0.004, 0.001). The maximal HbF response to HU in HbS/β+-thalassemia was 20%, similar to those observed for HbSS (19%) and HbS/β0-thalassemia (22%). HbS/β+-thalassemia could have a similar disease severity as HbSS or HbS/β0-thalassemia. Patients with HbS/β0-thalassemia or HbS/β+-thalassemia phenotypes responded to HU.

References Powered by Scopus

Mortality in sickle cell disease — life expectancy and risk factors for early death

2699Citations
N/AReaders
Get full text

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia

1988Citations
N/AReaders
Get full text

Global epidemiology of haemoglobin disorders and derived service indicators

1335Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Fetal hemoglobin in sickle cell anemia

70Citations
N/AReaders
Get full text

Current challenges in the management of patients with sickle cell disease - A report of the Italian experience

34Citations
N/AReaders
Get full text

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic

25Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Di Maggio, R., Hsieh, M. M., Zhao, X., Calvaruso, G., Rigano, P., Renda, D., … Maggio, A. (2018). Chronic administration of hydroxyurea (HU) benefits caucasian patients with sickle-beta thalassemia. International Journal of Molecular Sciences, 19(3). https://doi.org/10.3390/ijms19030681

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

71%

Lecturer / Post doc 2

12%

Researcher 2

12%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

48%

Biochemistry, Genetics and Molecular Bi... 6

26%

Nursing and Health Professions 4

17%

Materials Science 2

9%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free